CD74

Across TCGA pan-cancer cohorts, CD74 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CD74 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CD74 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CD74 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

GBM, COAD, and HNSC are the cancer types where CD74 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.283	0.480	.020	15	view →
COAD	DFS	Quartile	All	0.909	1.000	.042	12	view →
HNSC	DFS	Quartile	All	0.900	1.000	.013	6	view →
CCRCC	DFS	Median	II,III,IV	1.000	0.514	.022	3	view →
UCEC	OS	Median	All	0.982	0.912	.032	2	view →
PDAC	OS	Median	III,IV	0.904	0.619	.035	2	view →
LSCC	DFS	Median	All	0.929	0.615	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CD74–GBM (OS)

Open the GBM breakdown →